Abstract: A process for treating a heavy byproduct stream from an initial chlorinated propane forming reaction in order to increase the final output of chlorinated propene and remove metal catalyst. In particular, the process disclosed herein provides for a primary stream in which chlorinated propanes are converted to chlorinated propenes in a catalytic dehydrochlorination reaction, while also treating a separate byproduct stream with a caustic to precipitate metal from a metal catalyst and convert any remaining chlorinated propanes to chlorinated propenes in order to increase final chlorinated propene output.

Abstract: Two methods for reducing CFC impurities and, in particular, CFC-114, in the HFO-1234ze(E) production process from the reaction of CFC-113 and HF. The first method involves subjecting an intermediate or recycle stream to separation and distillation to purge CFC-113 from the process. The second method involves operating the separation at a higher pressure avoids the formation of an azeotrope between CFC-113 and HFC-245fa. The CFC-113/HFC245fa azeotrope is discussed, as well as other optional processes for removal or mitigation of CFC-113 which include further separations that remove CFC-114 from the HFO-1234ze(E) product and/or CFC-113 from the HFC-245fa feed to produce an HFO-1234ze(E) product that is largely free from CFC-114 and other CFC impurities.

Abstract: Provided is a method for storing a fluorobutene by which polymerization is unlikely to proceed during storage. A fluorobutene represented by general formula C4HxFy where x is 0 or more and 7 or less, y is 1 or more and 8 or less, and x+y is 8 contains or does not contain at least one of sodium, potassium, magnesium, and calcium as a metal impurity. The fluorobutene is stored in a container in which the total concentration of sodium, potassium, magnesium, and calcium is 1,000 ppb by mass or less when containing at least one of sodium, potassium, magnesium, and calcium.

Abstract: The invention comprises a process for the preparation of a chiral triol of formula I wherein, R1 is hydrogen or halogen by way of an asymmetric hydrogenation of a ketone compound of formula IIa wherein, R1 is hydrogen or halogen and R2 is C1-6-alkyl; with hydrogen in the presence of an iridium spiro-pyridylamidophosphine catalyst (Ir-SpiroPAP catalyst). The chiral triols of formula I are versatile building blocks for the preparation of various pharmaceutically active drug substances such as for instance for statins.

Abstract: The conversion of nootkatol to nootkatene in a terpene blend is mitigated or prevented by substantially or completely separating the nootkatols such as a-nootkatol from compounds present in the terpene blend that catalyze the chemical reaction of nootkatol to nootkatene, and/or by at least partially neutralizing the compounds present in the terpene blend that catalyze the chemical reaction of nootkatol to nootkatene. Methods of preparing terpene blends, terpene blends, flavour compositions containing the terpene blends, beverages and foodstuffs containing the flavour compositions, fragrance compositions containing the terpene blends, and fragranced products containing the fragrance composition are also disclosed.

Abstract: A method for controlling a reactive distillation column for effecting a transalcoholisation reaction, comprising feeding a metal methoxide into the reactive distillation column via a side feed; feeding a reactant alcohol into a lower part of the reactive distillation column; withdrawing methanol from the top of the reactive distillation column; and withdrawing a solution of a product metal alkoxide in the reactant alcohol from the bottom of the reactive distillation column; wherein the method comprises a process control scheme selected from: Scheme A: establishing a signal S1 which is responsive to a temperature in the rectifying section disposed above the feed of the metal methoxide; and manipulating in response to the signal S1 the feed amount of the reactant alcohol; Scheme B: establishing a signal S1 which is responsive to a temperature in the rectifying section disposed above the feed of the metal methoxide; and manipulating in response to the signal S1 the heat supplied to the bottom of the reactive dis

Abstract: Disclosed is a method for purifying cannabinoid compounds that enables cannabinoid compounds to be obtained more economically and with a better purification effect.

Abstract: Systems and methods for recovering phenol have been disclosed. At least a portion of a wastewater stream from a bisphenol-A production process and a phenol stream that is produced by separating a crude phenol stream from a cumene based phenol production process are concurrently processed in a hydrocarbon removal unit to produce (i) a purified phenol stream comprising 95 to 99.9 wt. % phenol and (ii) an aqueous stream comprising water and byproducts of the phenol production process.

Abstract: An object of the present disclosure is to provide a method for producing a fluorinated organic compound, the method being capable of removing a sulfur-containing substance to a high degree, or provide a composition containing a fluorinated organic compound with a low content of a sulfur-containing substance. The present disclosure relates to a method for producing a fluorinated organic compound (pf), the method comprising: [A] reaction step A of fluorinating an organic sulfur compound (ss) with a fluorinating agent to obtain a composition (?) containing a fluorinated organic compound (pf); and [B] post-treatment step B of reacting the composition (?) with a nucleophile at a temperature of 40° C. or higher.

Abstract: Provided are systems and methods for metal formate synthesis from carbon monoxide supplied by an electrolyzer having a membrane electrode assembly which incorporate the capacity to recover and recycle various chemical components of the production process. For the synthesis, carbon monoxide from an electrolyzer is reacted with a solubilized metal hydroxide in a batch process or a continuous process.

Abstract: Method for isolating carboxylic acid from an aqueous alkali metal carboxylate-containing side stream, e.g., the aqueous side stream of an organic peroxide production process, with co-production of alkali metal salt, involving adding an acid, or an anhydride, ketene or acid salt, to the aqueous side stream, thereby forming carboxylic acid and alkali metal salt within the aqueous side stream, and separation of the carboxylic acid from the aqueous side stream.

Abstract: The present disclosure provides a process for removing fluoroorganic acidic compounds from a solution comprising at least one protic solvent, comprising: forming a mixture of a solution comprising at least one fluoroorganic acidic compound comprising less than 15 carbon atoms and protic solvent, wherein the solution has a pH of 4, with an extraction composition comprising at least one trialkylamine and organic solvent; reacting the fluoroorganic acidic compound with the trialkylamine to form a hydrophobic ionic compound comprising the anion of the fluoroorganic acidic compound and the cation of the trialkylamine; separating the mixture into a first phase comprising the protic solvent and at most 50 wt.

Abstract: Methods for preparing isotopically modified 1,4-diene systems from non-isotopically modified 1,4-dienes involve selective oxidation of one or more bis-allylic position(s), or the preparation of isotopically modified 1,4-diene systems via trapping pi-allylic complexes with a source of deuterium or tritium. Such methods are useful for preparing isotopically modified polyunsaturated lipid including polyunsaturated fatty acids and polyunsaturated fatty acid derivatives.

Abstract: The present specification provides a method of preparing a heterogeneous linear carbonate, including transesterifying an aliphatic alcohol and a symmetric linear carbonate in the presence of a catalyst, wherein the catalyst is a porous type basic ion exchange resin having an exchange capacity of 1 (eq/l-wet resin) or more and 1.5 (eq/l-wet resin) or less. The preparation method of the present specification provides a method of preparing a heterogeneous, symmetric linear carbonate and asymmetric linear carbonate in high yield without a process of reactive distillation.

Abstract: The present disclosure describes hyperpolarized materials for use in nuclear magnetic resonance, magnetic resonance imaging, or similar applications. The present disclosure describes methods for producing hyperpolarized materials for use in nuclear magnetic resonance, magnetic resonance imaging, or similar applications. The present disclosure describes precursor compounds for use in producing hyperpolarized materials for use in nuclear magnetic resonance, magnetic resonance imaging, or similar applications.

Abstract: A separation and purification method of 2-nitroethanol, including: (a) reacting paraformaldehyde with nitromethane in the presence of a base to obtain a mixture of 2-nitroethanol (I), 2-nitro-1,3-propanediol (II) and tris(hydroxymethyl) nitromethane (III); and (b) selecting an extraction solvent in which 2-nitroethanol (I), 2-nitro-1,3-propanediol (II) and tris(hydroxymethyl) nitromethane (III) are different in solubility; adding the extraction solvent to the mixture followed by extraction, separation, and vacuum concentration to obtain the 2-nitroethanol (I).

Abstract: The present invention includes DNP derivatives that are useful for preventing or treating a metabolic disease or disorder in a subject in need thereof. In certain embodiments, the subject is further administered at least one additional therapeutic agent.

Abstract: The present invention provides processes for the preparation of fenfluramine and salts thereof, including reductive amination of 3-(trifluoromethyl) phenylacetone, as well as products prepared by such processes.

Abstract: The present invention relates to compounds and methods useful for selectively modulating mTORC1 activity.

Abstract: An improved process can be used for the acid hydrolysis of polylaurolactam with sulfuric acid. An especially suitable starting material is polylaurolactam which is intended for recycling and which is characterized by a low laurolactam content.

Abstract: The invention concerns new mono-ammonium compounds of formula (I) with surfactant properties and improved biodegradability. It concerns also new mixtures comprising such mono-ammonium compounds and di-ammonium compounds.

Abstract: The present invention relates to a long chain alkyl esteramine lipid compound as shown in Formula I, preparation method therefor as well as use thereof in nucleic acid delivery, the long chain alkyl esteramine lipid compound provided by the present invention has an excellent encapsulation rate and delivery effect as a lipid molecule in delivering disease treatment or preventive agents, showing lower toxicity and certain tissue distribution characteristics, and providing a basis of more selections for delivering disease therapeutic or prophylactic agents.

Abstract: Composition and methods for killing microorganisms using antimicrobial epoxy polymers and epoxy polymer curing agents are described. Compositions containing at least one compound of formula I where R1 is a phenolic group (e.g., simple phenol, creosote, thymol, or carvacrol), and where R2 is a polyamine (e.g., ethylenediamine (EDA), diethylenetriamine (DETA), triethylenetetramine (TETA), tetraethylenepentamine (TEPA), hexamethylenediamine (HDA)); and optionally a carrier; the compositions may additionally contain at least one epoxy resin. Methods for killing microorganisms involving contacting the microorganisms with an effective microorganism killing amount of the above composition.

Abstract: The present invention relates to a process for preparing hexanoic acid, 6-(nitrooxy)-, (1S,2E)-3-[(1R,2R,3S,5R)-2-[(2Z)-7-(ethylamino)-7-oxo-2-hepten-1-yl]-3,5-dihydroxycyclopentyl]-1-(2-phenylethyl)-2-propen-1-yl ester In accordance with the present invention, a pharmaceutical grade Compound (I) can be efficiently prepared by a one-pot reactions preparation step that includes the esterification of the 15-OH bimatoprost by coupling bimatoprost phenyl-boronate with 6-(nitrooxy)hexanoic acid and the removal of the boronate ester protecting group, followed by an efficient purification step. The invention refers also to high purity Compound (I) substantially free of the impurity 15-(6-chlorohexanoyl) ester of bimatoprost and to ophthalmic pharmaceutical formulations containing the high purity compound.

Abstract: The present invention relates to a process for preparing a polyisocyanate, namely an isocyanate group-terminated polyol polyanthranilic acid ester. The process comprises the step of reacting an anthranilic acid derivative selected from anthranilic acid halide (in particular anthranilic acid chloride), isatoic anhydride or a mixture thereof with a first polyol of a number-average molar mass of at least 200 g/mol and a functionality in the range of 2 to 8, and obtaining, as a result, a polyamine (namely a polyol polyanthranilic acid ester with amine terminal groups) and reacting the polyamine with phosgene and obtaining, as a result, a polyisocyanate (namely an isocyanate group-terminated polyol polyanthranilic acid ester). The invention further relates to the polyisocyanates obtained in this way, their use in polyaddition reactions, and polyaddition products obtainable by these reactions.

Abstract: The present invention relates to carbamoyl phenylalaninol compounds and methods of using the same to treat disorders.

Abstract: The present disclosure relates to the synthesis of prostate specific membrane antigen (PSMA) ligands that are useful in the treatment of diseases like cancer. In particular, the disclosure relates to a method for synthesizing PSMA ligands having a glutamate-urea-lysine (GUL) moiety and a chelating agent that can comprise a radiometal.

Abstract: The present invention relates to a process for producing methyl mercaptan, comprising the following steps: A) methanol is reacted with hydrogen sulfide to form a stream (M), preferably in gaseous form, comprising methyl mercaptan, unreacted H2S and possibly sulfur byproducts; B) optionally, said stream (M) is condensed; C) at least one step of purification of said stream (M) is performed to obtain a stream enriched in methyl mercaptan; D) the gaseous vents resulting from said at least one purification step are recovered, said gaseous vents comprising at least one sulfur compound, preferably H2S; E) a gas-liquid extraction of said at least one sulfur compound, preferably H2S, is performed with liquid methanol so as to obtain a liquid methanol enriched in sulfur compound(s), preferably in H2S; and F) optionally, said enriched methanol is used as reagent for the reaction of step A).

Abstract: Multifunctional amine-containing bolaamphiphilic compositions comprising hydrocarbon terpenes, methods of preparing such compositions, and the use of these compositions in gene delivery applications are disclosed.

Abstract: This disclosure relates to LPA antagonists of Formula (I): including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.

Abstract: The present invention relates to 3-hydroxyoxindole derivatives which have antagonistic activities against CRHR2, and which are useful in the treatment or prevention of disorders and diseases in which CRHR2 is involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CRHR2 is involved.

Abstract: Provided are a compound capable of improving the light-emitting efficiency, stability, and lifespan of an element; an organic electronic element using same; and an electronic device thereof.

Abstract: Disclosed are a series of compounds or their tautomers having a general structure represented by Formula Ia or Ib and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions comprising said compounds or tautomers or pharmaceutically acceptable salts thereof. Further disclosure relates to a method of treating a disease or condition associated with iron dysregulation or dysfunctional iron homeostasis, comprising administering to a subject in need thereof a therapeutically effective amount of Formula Ia or Ib compounds or tautomers or pharmaceutically acceptable salts thereof.

Abstract: The present invention discloses a process for the preparation of substituted pyridine compounds of formula (I), comprises a step in which vinylogous nitriles of formula (II), are obtained from substituted ?,?-unsaturated nitrile compounds of formula (III), and a further step of converting the vinylogous nitrile compounds of formula (II) into substituted pyridines of formula (I); wherein R1, R2, R3, R4 and LG are as defined in the description.

Abstract: The present invention relates to a new process for manufacturing (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4?,5?:5,6]benzo[1,2-g]quinoline with formula (Ib) below, (4aR,10aR)-1-Propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol with formula (I) below and salts thereof. Both compounds are for use in the treatment of neurodegenerative diseases and disorders such as Parkinson's Disease. The invention also relates to new intermediate compounds of said process.

Abstract: Disclosed herein are compounds, 6-substituted-2-([1,1?-biphenyl]-4-yl)quinoline-4-carboxylic acid analogs, that are inhibitors of dihydroorotate dehydrogenase (DHODH) with improved pharmacokinetic properties. The disclosed compounds can be used in the treatment of a variety of disorders and diseases in which inhibition of DHODH can be clinically useful, including cancer, such as a hematological cancer, including acute myeloid leukemia (AML); graft-versus-host-diseases; autoimmune disorders; and disorders associated with T-cell proliferation. The disclosed compounds can demonstrate flip-flop kinetics when administered orally, i.e., pharmacokinetics in which the rate of absorption, rather than the rate of elimination, dominates the pharmacokinetics. The disclosed compounds can demonstrate a sustained pharmacokinetic profile instead of an immediate release profile.

Abstract: Disclosed are a method for the synthesis of roxadustat and an intermediate thereof, and an intermediate thereof. In particular, disclosed is a method for the synthesis of compound M1, the method comprising the following steps: carrying out a reaction as shown below between compound SM and compound SM-A under the action of an oxidizing agent. The method of the present invention uses cheap and easily available raw materials, has short reaction steps, produces a high yield, has simple and convenient post-treatment procedures, and is suitable for industrial production.

Abstract: The present invention relates to radiolabelled compounds for in vivo imaging or treatment of diseases or conditions characterized by expression of prostate-specific membrane antigen.

Abstract: The invention relates to compounds of formula (I): wherein A, RA1, RA2, RB, RC and RD are as defined herein, and associated aspects.

Abstract: The invention relates to a compound, to a rubber mixture containing the compound, to a vehicle tire comprising the rubber mixture in at least one component, to a process for producing the compound and to the use of the compound as an aging stabilizer and/or antioxidant and/or antiozonant and/or dye. The compound according to the invention has the formula I).

Abstract: [Problem] A compound which is useful as a STING inhibitor is provided. [Means for Solution] The present inventors have found aryl alkynamide derivatives having an inhibitory action on STING. The aryl alkynamide derivatives of the present invention have an inhibitory action on STING and can be used as an agent for treating an autoimmune disease, a neurodegenerative disease, a type I interferonopathy and/or other STING-mediated disease.

Abstract: Disclosed is a preparation method for cannflavin compounds. The preparation method has the advantages of cheap and easily available raw materials, few reaction steps, short production period, simple operation, etc. The method comprises: firstly, condensing 4?-hydroxy-3?-methoxyacetophenone and diethyl carbonate (DEC) under an alkaline condition to obtain 4?-hydroxy-3?-methoxybenzoyl acetate; reacting 1,3,5-trihydroxybenzene with bromo-isoamylene under an alkaline condition to obtain 2-isopentenyl-1,3,5-trihydroxybenzene; and finally, condensing 4?-hydroxy-3?-methoxybenzoyl acetate and 2-isopentenyl-1,3,5-trihydroxybenzene at a high temperature to produce cannflavin B and/or isocannflavin B, and then subjecting same to separation and purification to obtain pure cannflavin B and pure isocannflavin B.

Abstract: The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I): or pharmaceutically acceptable salts thereof wherein R, R1, R2, R3, R4, R5, R6, R7, and R8, are as defined herein. The disclosure also relates to methods of making and using compounds of Formula (I) or pharmaceutically acceptable salts thereof.

Abstract: This disclosure provides a method for converting CBD to a tetrahydrocannabinol featuring the use of cheap and non-toxic aluminum isopropoxide as a catalyst. The method comprises (a) providing a reaction mixture comprising a catalyst in an organic solvent, wherein the catalyst comprises aluminum isopropoxide; (b) adding a reagent comprising CBD to the reaction mixture; (c) mixing the reaction mixture and allowing a reaction for converting CBD to a tetrahydrocannabinol to occur for a predetermine period of time; (d) removing the catalyst by filtration upon the completion of the reaction; (e) removing the organic solvent; and (f) eluting the tetrahydrocannabinol from the organic phase.

Abstract: The present invention includes a novel class of MDMA carbamates that can be activated in vivo as prodrugs. The MDMA prodrugs of the invention are enzymatically cleaved in vivo and produce alcohols of low toxicity that are well tolerated and metabolized in humans.

Abstract: The invention provides tricyclic compounds that degrade neosubstrates for use in the treatment of disorders described herein, including, for example, abnormal cellular proliferation, neurodegenerative diseases, and autoimmune diseases.

Abstract: Disclosed are a carboxamide derivative and a pharmaceutical composition comprising same as an active ingredient for use in preventing or treating mental illness. The derivative is superbly effective in a triple reuptake inhibitor of serotonin, norepinephrine, and dopamine, and thus can be effectively used in treating mental illness.

Abstract: Provided herein are substituted 1,1,1,3,3,3-hexafluoropropan-2-yl 6-azaspiro[2.5]octane-6-carboxylate compounds and pharmaceutical compositions comprising said compounds. The compounds and compositions provided herein are useful as inhibitors of MAGL. Furthermore, the compounds and compositions as provided herein are useful for the treatment of diseases and disorders benefiting from the inhibition of MAGL.

Abstract: Pharmaceutical compositions include heteroaromatic compounds having a disease-modifying action in the treatment of fungal infections and diseases associated with fungal infection.

Abstract: The present invention relates to a compound of general formula (I) inhibiting the transforming growth factor-? (TGF-?) type I receptor (ALK5), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of ALK5 signaling pathway in a mammal.